- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03941678
Creatine Supplementation During Resistance Training for People Recovering From Stroke
The Effect of Creatine Supplementation and Resistance Training in Stroke Survivors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to determine the effects of creatine supplementation and supervised resistance training in stroke survivors. It is hypothesized that creatine supplementation and resistance training will increase whole-body lean tissue mass, limb muscle thickness, muscle strength, tasks of functionality and cognition and decrease symptoms of depression and anxiety compared to placebo and resistance training.
Stroke is characterized by an abrupt disturbance in cerebral circulation causing a neurological deficit. It is a major cause of adult neurological disability in North America, often resulting in significant muscle loss, weakness and functional limitations. Disability associated with stroke limits independent living and social participation in at least half of all stroke survivors. A sedentary lifestyle after stroke can increase the risk for recurrent stroke, cardiovascular disease, and diabetes mellitus. All factors may adversely affect independence and quality of life. The majority of stroke survivors have residual impairments such as hemiparesis, spasticity, cognitive dysfunction, and aphasia, with full recovery reached in a small portion of these individuals. One of the major consequences of these impairments is physical inactivity which inevitably contributes to muscle loss, decreased muscle function (i.e. strength, endurance) and impaired functionality. One intervention which may help improve muscle mass, muscle function and functionality in stroke survivors is supervised resistance training. Resistance training does not lead to muscle spasticity in stroke survivors and has been shown to improve the ability to perform activities of daily living. Another intervention which may be beneficial for stroke survivors is creatine supplementation. Creatine has been shown to increase muscle mass, muscle function and tasks of functionality when combined with resistance training, possibly by influencing cellular hydration status, high-energy phosphate metabolism, muscle protein kinetics, satellite cells, anabolic growth factors, and inflammation. Creatine has also shown promise for improving cognition and symptoms of depression and anxiety; however, no study has examined the combined effects of creatine supplementation and resistance training in stroke survivors.
The study will be a double-blind, repeated measures design. In order to minimize group differences, participants will be matched according to age, gender, and type of stroke and then be randomized on a 1:1 basis to one of two groups, creatine monohydrate or placebo (corn-starch maltodextrin). Creatine and placebo will be similar in taste, color, texture and appearance. A research assistant will be responsible for randomization and another research assistant will prepare study kits. Each study kit will contain the participants supplement for the duration of the study, detailed supplementation instructions, as well as measuring spoons. For days 1-7, participants will ingest 0.3g/kg of creatine or placebo (0.075 g/kg x 4 times daily). This creatine dosing strategy has been shown to be effective for increasing intramuscular creatine stores. For subsequent days, participants will consume 0.1 g/kg/day of creatine or placebo as this creatine dosage is effective for increasing muscle mass. On training days, participants will consume their supplement within 5 minutes after each training session. On non-training days, supplements will be consumed at the participants leisure. Adherence with creatine supplementation, placebo, and resistance training will be assessed by training and supplementation compliance logs. A retrospective treatment identification will be administered to all participants upon completion of the study in order to assess whether participants thought they were administered creatine, placebo, or unsure about what supplement they consumed.
The dependent variables that will be measured at baseline and after the intervention include: (1) whole-body lean tissue mass (dual energy x-ray absorptiometry) (2) muscle thickness (elbow and knee flexors and extensors; ultrasonography), (3) muscle strength (1-repetition maximum leg press and chest press), (4) tasks of functionality (berg balance scale, 6-minute walk test) (5) cognition (Montreal Cognitive Assessment), (6) depression (The Center for Epidemiologic Studies- Depression Scale) and anxiety (Generalized Anxiety Disorder 7-item). Participants will also complete a 3-day food log at baseline and during the last week of supplementation and training to determine whether total calories consumed as well as macronutrient intake changed over the duration of the study. Participants will be instructed to record all food and beverages consumption during these 3 days. Food records will be analyzed using MyFitnessPal.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Saskatchewan
-
Regina, Saskatchewan, Canada, S4S 0A2
- Faculty of Kinesiology and Health Sciences, University of Regina
-
Saskatoon, Saskatchewan, Canada, S7N5B2
- College of Kinesiology, University of Saskatchewan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least 6 months post-stroke
Exclusion Criteria:
- creatine supplementation within the past 12 weeks
- medications affecting muscle function within the past 12 weeks
- kidney disorders
- liver disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Creatine
0.3 g/kg/d creatine for 7 days; 0.1 g/kg/d creatine for 63 days
|
0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
|
Placebo Comparator: Placebo
0.3 g/kg/d placebo for 7 days; 0.1 g/kg/d placebo for 63 days
|
0.3 g/kg/day for 7 days; 0.1 g/kg/day for 63 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Walking ability
Time Frame: Change from baseline to 10 weeks
|
6-minute walk test (maximal distance)
|
Change from baseline to 10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lean tissue mass
Time Frame: Change from baseline to 10 weeks
|
Lean tissue mass determined by DXA
|
Change from baseline to 10 weeks
|
Leg muscle thickness
Time Frame: Change from baseline to 10 weeks
|
Knee extensor muscle thickness by ultrasound
|
Change from baseline to 10 weeks
|
Arm muscle thickness
Time Frame: Change from baseline to 10 weeks
|
Biceps muscle thickness by ultrasound
|
Change from baseline to 10 weeks
|
Leg strength
Time Frame: Change from baseline to 10 weeks
|
Leg press 1-repetition maximum
|
Change from baseline to 10 weeks
|
Upper body strength
Time Frame: Change from baseline to 10 weeks
|
Chest press 1-repetition maximum
|
Change from baseline to 10 weeks
|
Balance
Time Frame: Change from baseline to 10 weeks
|
Berg balance scale to measure balance.
Includes 14 sub-scales which are summed.
Scoring range is from 0 (worse) to 56 (best)
|
Change from baseline to 10 weeks
|
Cognition
Time Frame: Change from baseline to 10 weeks
|
Montreal cognitive assessment to assess cognitive ability.
Seven sub-scales which are summed.
Scoring range is from 0 (worse) to 30 (best)
|
Change from baseline to 10 weeks
|
Anxiety
Time Frame: Change from baseline to 10 weeks
|
General Anxiety Disorder Assessment to assess anxiety.
Seven questions whose scores are summed.
Scoring range is from 0 (least anxious) to 21 (most anxious)
|
Change from baseline to 10 weeks
|
Depression
Time Frame: Change from baseline to 10 weeks
|
Center for Epidemiologic Depression (CES-D) Scale to assess depression.
Twenty questions whose scores are summed.
Scoring range is from 0 (least depressed) to 60 (most depressed)
|
Change from baseline to 10 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 001 (NavyGHB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
Clinical Trials on Creatine monohydrate
-
Texas A&M UniversityNutraboltCompletedDietary Modification
-
Texas A&M UniversityNutraboltCompletedDietary Supplementation
-
Massachusetts General HospitalCompletedHuntington's Disease (HD)United States
-
Dynamical Business and Science Society - DBSS International...CES University; INDEPORTES AntioquiaCompleted
-
The Cleveland ClinicCompletedHypercholesterolemia | Weakness | Cramps | AchesUnited States
-
Perry RenshawCompletedMajor Depressive DisorderUnited States
-
University of UtahNational Cancer Institute (NCI)RecruitingFatigue | Sedentary Lifestyle | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC (American Joint Committee on Cancer) v8 | Stage IVA Prostate Cancer AJCC (American Joint Committee on Cancer) v8 | Stage IVB Prostate Cancer AJCC (American Joint Committee on Cancer) v8United States
-
Beth Israel Medical CenterCompleted
-
University of Kansas Medical CenterAlzheimer's AssociationRecruiting
-
Psychiatric Research Unit, Region Zealand, DenmarkUniversity of Southern DenmarkNot yet recruitingMild Traumatic Brain Injury | Concussion, Brain